Stockscreener 앱 받기
2.50
4.58%
-0.12
시간 외 거래:
2.55
0.05
+2.00%
Black Diamond Therapeutics Inc 주식(BDTX)의 최신 뉴스
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Decrease in Short Interest - MarketBeat
T. Rowe Price Investment Management, Inc. Expands Stake in Black Diamond Therapeutics Inc - GuruFocus.com
Vestal Point Capital, LP Increases Stake in Black Diamond Therap - GuruFocus.com
What is HC Wainwright's Estimate for BDTX FY2024 Earnings? - MarketBeat
Wedbush Has Optimistic View of BDTX FY2024 Earnings - MarketBeat
Black Diamond Therapeutics (NASDAQ:BDTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Black Diamond Therapeutics Reports Promising Q3 2024 Results - TipRanks
Black Diamond: Q3 Earnings Snapshot - San Francisco Chronicle
BDTXBlack Diamond Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St
Black Diamond's BDTX-1535 Shows 42% Response Rate in Lung Cancer Trial, Reports Q3 Results | BDTX Stock News - StockTitan
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Growth in Short Interest - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Up 5.9% in October - MarketBeat
Foundations Investment Advisors LLC Has $445,000 Stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) looking to reclaim success with recent performance - SETE News
Investing in Black Diamond Therapeutics Inc (BDTX) Is Getting More Attractive - Knox Daily
Results from Black Diamond Therapeutics Inc (BDTX) show potential - US Post News
Market Update: Black Diamond Therapeutics Inc (BDTX) Sees Negative Movement, Closing at 3.33 - The Dwinnex
Dimensional Fund Advisors LP Has $932,000 Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Black Diamond Therapeutics Inc [BDTX] Records 200-Day SMA of $4.87 - Knox Daily
FY2024 EPS Estimates for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Increased by Analyst - MarketBeat
Analysts’ Recent Ratings Changes for Black Diamond Therapeutics (BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) is looking forward to a strong quarter - SETE News
Cuts for Black Diamond as runway's end nears - The Pharma Letter
Q3 2024 Earnings Estimate for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Issued By Wedbush - MarketBeat
Layoffs at local cancer drug developer; Flagship names new managing partner - The Business Journals
Black Diamond Therapeutics (NASDAQ:BDTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data (BDTX) - Seeking Alpha
Black Diamond refocuses on lead cancer drug, extends cash runway - Investing.com India
Black Diamond Therapeutics (NASDAQ:BDTX) Given Outperform Rating at Wedbush - MarketBeat
Piper Sandler maintains Overweight rating on Black Diamond Therapeutics shares - Investing.com Canada
Black Diamond Therapeutics Inc (BDTX) Becoming More Attractive for Investors - Knox Daily
Black Diamond Therapeutics Inc (BDTX) stock analysis: A simple moving average approach - US Post News
Market Highlights: Black Diamond Therapeutics Inc (BDTX) Ends on a Low Note at 3.66 - The Dwinnex
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway - ForexTV.com
Black Diamond Therapeutics Restructures to Focus on Oncology Lead Program - TipRanks
Black Diamond Therapeutics to Cut Jobs Amid Restructuring, Names New CFO - MarketWatch
Black Diamond CFO departs as part of restructuring, job cuts - Seeking Alpha
Black Diamond refocuses on lead cancer drug, extends cash runway By Investing.com - Investing.com Canada
Black Diamond Therapeutics Announces Restructuring Plan to - GlobeNewswire
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway - GlobeNewswire Inc.
Black Diamond Therapeutics Inc [NASDAQ: BDTX] Sees Decrease in Stock Value - Knox Daily
Black Diamond Therapeutics Inc (BDTX) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
It is Poised to be a Bull Market for Black Diamond Therapeutics Inc (BDTX) - SETE News
Analyzing Black Diamond Therapeutics Inc (BDTX) After Recent Trading Activity - Knox Daily
Stock Surge: Black Diamond Therapeutics Inc (BDTX) Closes at 4.23, Marking a -4.08 Increase/Decrease - The Dwinnex
Black Diamond Therapeutics Inc (BDTX) stock analysis: A comprehensive overview - US Post News
A company insider recently sold 221,600 shares of Black Diamond Therapeutics Inc [BDTX]. Should You Sale? - Knox Daily
A look into Black Diamond Therapeutics Inc (BDTX)’s deeper side - SETE News
Affinity Asset Advisors LLC Invests $3.03 Million in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BlackGold Secures Critical Extension for Proposal - TipRanks
Bank of New York Mellon Corp Buys 18,664 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
3.66%
1.11%
자본화:
|
볼륨(24시간):